EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a high-throughput screening platform for C. difficile toxin synthesis inhibitors unveils meclizine as an antivirulence agent

Ravi K R Marreddy, Nghi Nguyen, Chetna Dureja, Ann Marie McKelvey, Reid Powell, Abiola O Olaitan iD, Clifford Stephan, Julian G Hurdle iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00960-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Ravi K R Marreddy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Clostridioides difficile, High-Throughput Screening Assays, Bacterial Toxins, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Cancer Prevention and Research Institute of Texas, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clostridioides difficile, a leading cause of hospital-acquired diarrhea, exerts its virulence through two co-regulated toxins, TcdA and TcdB. Despite their pivotal roles, the discovery of inhibitors targeting their biosynthesis is underexplored. Here, we present a high-throughput screening (HTS) platform designed to identify toxin synthesis inhibitors (TSIs) that minimally impact bacterial growth. The primary screen utilized a C. difficile reporter strain expressing secreted Nano-luciferase (secNluc) under the tcdA promoter, whereby inhibition of secNluc production indicates toxin biosynthesis inhibition. Screening the Prestwick Chemical Library at 10 and 100 µM identified several compounds that reduced secNluc activity. Through counter-screening, we eliminated compounds that caused spectral interference. Orthogonal dose-response assays assessing the effectiveness of inhibiting toxin production without affecting growth identified meclizine, an antihistamine, as the primary antivirulence candidate. Meclizine was confirmed as a TSI by showing that it reduced TcdA and TcdB protein levels, the cytopathic potential of cultures, and tcdA and tcdB transcription as determined by ELISA, cell-rounding assays, and RT-qPCR, respectively. Meclizine significantly altered central carbon metabolism in C. difficile , upregulating carbohydrate transport systems and the conversion of lactate to pyruvate, while downregulating glycolytic genes. These changes were associated with intracellular accumulation of glucose and pyruvate, metabolites known to negatively impact toxin production. Taken together, our findings underscore the utility of the above HTS platform to identify anti- C . difficile TSIs, which can serve as molecular and cellular probes, as well as chemical starting points for developing novel therapeutics for C. difficile infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridioides difficileHigh-Throughput Screening AssaysBacterial ToxinsAnti-Bacterial AgentsEnterotoxinsBacterial ProteinsMicrobial Sensitivity TestsVirulenceHumans

Stichwörter der Autor:innen

Clostridioides difficileassay developmentluciferasesmall-molecule inhibitor screeningtoxins

Substanzen

Bacterial ToxinsAnti-Bacterial AgentsBacterial ProteinsEnterotoxinstcdA protein, Clostridium difficiletoxB protein, Clostridium difficile

Autor:innen und Institutionen

  • Center for Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas, USA.
  • Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas, USA.

ORCID-Profile: Abiola O Olaitan, Julian G Hurdle

Förderung

  • NIAID NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Zitieren

APA

Marreddy, R. K. R., Nguyen, N., Dureja, C., McKelvey, A. M., Powell, R., Olaitan, A. O., Stephan, C., & Hurdle, J. G. (2026). Development of a high-throughput screening platform for C. difficile toxin synthesis inhibitors unveils meclizine as an antivirulence agent. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00960-25

Vancouver

Marreddy RKR, Nguyen N, Dureja C, McKelvey AM, Powell R, Olaitan AO, et al. Development of a high-throughput screening platform for C. difficile toxin synthesis inhibitors unveils meclizine as an antivirulence agent. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00960-25

BibTeX
@article{Marreddy2026,
  author = {Marreddy, Ravi K R and Nguyen, Nghi and Dureja, Chetna and McKelvey, Ann Marie and Powell, Reid and Olaitan, Abiola O and Stephan, Clifford and Hurdle, Julian G},
  title = {Development of a high-throughput screening platform for C. difficile toxin synthesis inhibitors unveils meclizine as an antivirulence agent},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00960-25}
}
Kostenlos starten →